Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hodgson

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Current Opinion in Drug Discovery & Development|July 3, 2010
Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's diseaseUnmesh Shah, Robert Hodgson
Organic & Biomolecular Chemistry|January 30, 2004
A two-directional synthesis of the C58-C71 fragment of palytoxinRobert Hodgson, Adam Nelson
Pharmacoeconomics|February 24, 2026
Schrodinger's Pricing: Conceptual and Practical Challenges of Conditional PAS in the NICE Technology Appraisal of Lorlatinib for Untreated ALK-Positive Advanced Non-small-cell Lung Cancer (Review of TA1103): An External Assessment Group PerspectiveRobert Hodgson, Diarmuid Coughlan
Journal of Health Economics|August 23, 2011
"It's driving her mad": Gender differences in the effects of commuting on psychological healthJennifer Roberts, Robert Hodgson, Paul Dolan
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 6, 2024
Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient AccessMartin W Njoroge, Matthew Walton, Robert Hodgson
Psychopharmacology|October 24, 2013
MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348Steven M Grauer, Robert Hodgson, Lynn A Hyde
Journal of Clinical Epidemiology|July 16, 2017
Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overviewNerys Woolacott, Mark Corbett, Julie Jones-Diette, et al.
Pharmacoeconomics|September 5, 2016
A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the EvidenceRos Wade, Robert Hodgson, Mousumi Biswas, et al.
Pharmacoeconomics|April 15, 2019
Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology AppraisalMatthew Walton, Sahar Sharif, Mark Simmonds, et al.
Pharmacoeconomics|December 2, 2017
Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRobert Hodgson, Matthew Walton, Mousumi Biswas, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Current Opinion in Drug Discovery & Development|July 3, 2010
Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's diseaseUnmesh Shah, Robert Hodgson
Organic & Biomolecular Chemistry|January 30, 2004
A two-directional synthesis of the C58-C71 fragment of palytoxinRobert Hodgson, Adam Nelson
Pharmacoeconomics|February 24, 2026
Schrodinger's Pricing: Conceptual and Practical Challenges of Conditional PAS in the NICE Technology Appraisal of Lorlatinib for Untreated ALK-Positive Advanced Non-small-cell Lung Cancer (Review of TA1103): An External Assessment Group PerspectiveRobert Hodgson, Diarmuid Coughlan
Journal of Health Economics|August 23, 2011
"It's driving her mad": Gender differences in the effects of commuting on psychological healthJennifer Roberts, Robert Hodgson, Paul Dolan
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 6, 2024
Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient AccessMartin W Njoroge, Matthew Walton, Robert Hodgson
Psychopharmacology|October 24, 2013
MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348Steven M Grauer, Robert Hodgson, Lynn A Hyde
Journal of Clinical Epidemiology|July 16, 2017
Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overviewNerys Woolacott, Mark Corbett, Julie Jones-Diette, et al.
Pharmacoeconomics|September 5, 2016
A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the EvidenceRos Wade, Robert Hodgson, Mousumi Biswas, et al.
Pharmacoeconomics|April 15, 2019
Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology AppraisalMatthew Walton, Sahar Sharif, Mark Simmonds, et al.
Pharmacoeconomics|December 2, 2017
Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRobert Hodgson, Matthew Walton, Mousumi Biswas, et al.
Pageof 7